A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

This study is testing a new drug called BMS-986523 — alone or combined with other cancer drugs — in adults with advanced solid tumors (cancers in organs or tissues, not blood cancers) that have a specific genetic change in a gene called KRAS. KRAS mutations are found in many cancers and have historically been difficult to treat. **You may be eligible if...** - You are an adult with a solid tumor cancer that has been confirmed by biopsy - Your tumor has been tested and found to have a KRAS mutation or KRAS amplification - You have already tried standard treatments, are not eligible for them, or have chosen not to receive them after full discussion with your doctor - For one particular treatment arm (Arm D): your tumor must express a high level of a protein called PD-L1 (50% or more) **You may NOT be eligible if...** - You have brain metastases that have not yet been treated - You have another active cancer requiring treatment, or had a cancer within the past 2 years - You have a history of serious lung inflammation (interstitial lung disease or pneumonitis) - You have had a prior severe skin reaction to any drug (such as Stevens-Johnson Syndrome) Talk to your doctor to see if this trial is right for you.